One-shot immunization with Sputnik Light (the first component of Sputnik V vaccine) is effective against SARS-CoV-2 Delta variant: efficacy data on the use of the vaccine in civil circulation in Moscow
Objectives Vaccination remains the most effective response to the COVID-19 pandemic. Most vaccines use two-dose regimens. In turn, single-dose vaccines also have high potential, since, on the one hand, they simplify the vaccination program, make it more accessible and convenient for more people around the world, and on the other hand, they are better suited for subsequent revaccination. However, there is not enough data on the effectiveness of single-dose vaccine variants against new genetic lines to assess their current potential. It is not clear how much a single dose of immunization protects against the globally dominant delta variant. In this work, we investigated the effectiveness of a single dose vaccine (Sputnik Light, the first component of Sputnik V vaccine) against the Delta variant in Moscow.Methods To assess the effectiveness of one dose of viral vector vaccine based on rAd26 against the delta variant in Moscow, we used data from the Moscow registries of vaccination against COVID-19 and the incidence of COVID-19. The availability of data on the number of seropositive residents of Moscow made it possible to consider the size of the immune layer formed because of a previous COVID-19 disease or vaccination. To calculate the effectiveness, the proportion of COVID-19 cases among those vaccinated with a single dose and the proportion of cases among those who were not vaccinated in July 2021.Results Our data indicate that throughout July 2021, the dominant variant of the coronavirus at the level of 99.5% in Moscow was the SARS-CoV-2 delta variant and its subsidiary lines. Considering the immune layer of 46% allowed us to calculate the effectiveness of a one-shot vaccine against the delta variant in Moscow during the first three months after vaccination at the level of 69.85% (95% confidence interval [CI], 64.08 to 74.70). In the 18-29-year-old group, the overall vaccine efficacy against the delta variant was 88.61%, in the 18-59 group - 75.28%. Sputnik Light demonstrates higher efficacy against Delta variant than many two-shot vaccines.Conclusion The results indicate a high efficacy of a single immunization first component of Sputnik V vaccine against delta variant among young and middle-aged people, at least during the first 3 months after receiving the one-shot vaccine..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
bioRxiv.org - (2021) vom: 16. Okt. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.1101/2021.10.08.21264715 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI032793731 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI032793731 | ||
| 003 | DE-627 | ||
| 005 | 20230429093639.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211015s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.10.08.21264715 |2 doi | |
| 035 | |a (DE-627)XBI032793731 | ||
| 035 | |a (biorXiv)10.1101/2021.10.08.21264715 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Dolzhikova, Inna V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a One-shot immunization with Sputnik Light (the first component of Sputnik V vaccine) is effective against SARS-CoV-2 Delta variant: efficacy data on the use of the vaccine in civil circulation in Moscow |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Objectives Vaccination remains the most effective response to the COVID-19 pandemic. Most vaccines use two-dose regimens. In turn, single-dose vaccines also have high potential, since, on the one hand, they simplify the vaccination program, make it more accessible and convenient for more people around the world, and on the other hand, they are better suited for subsequent revaccination. However, there is not enough data on the effectiveness of single-dose vaccine variants against new genetic lines to assess their current potential. It is not clear how much a single dose of immunization protects against the globally dominant delta variant. In this work, we investigated the effectiveness of a single dose vaccine (Sputnik Light, the first component of Sputnik V vaccine) against the Delta variant in Moscow.Methods To assess the effectiveness of one dose of viral vector vaccine based on rAd26 against the delta variant in Moscow, we used data from the Moscow registries of vaccination against COVID-19 and the incidence of COVID-19. The availability of data on the number of seropositive residents of Moscow made it possible to consider the size of the immune layer formed because of a previous COVID-19 disease or vaccination. To calculate the effectiveness, the proportion of COVID-19 cases among those vaccinated with a single dose and the proportion of cases among those who were not vaccinated in July 2021.Results Our data indicate that throughout July 2021, the dominant variant of the coronavirus at the level of 99.5% in Moscow was the SARS-CoV-2 delta variant and its subsidiary lines. Considering the immune layer of 46% allowed us to calculate the effectiveness of a one-shot vaccine against the delta variant in Moscow during the first three months after vaccination at the level of 69.85% (95% confidence interval [CI], 64.08 to 74.70). In the 18-29-year-old group, the overall vaccine efficacy against the delta variant was 88.61%, in the 18-59 group - 75.28%. Sputnik Light demonstrates higher efficacy against Delta variant than many two-shot vaccines.Conclusion The results indicate a high efficacy of a single immunization first component of Sputnik V vaccine against delta variant among young and middle-aged people, at least during the first 3 months after receiving the one-shot vaccine. | ||
| 700 | 1 | |a Gushchin, Vladimir A |e verfasserin |4 aut | |
| 700 | 1 | |a Shcheblyakov, Dmitry V |e verfasserin |4 aut | |
| 700 | 1 | |a Tsybin, Alexander N. |e verfasserin |4 aut | |
| 700 | 1 | |a Shchetinin, Alexey M |e verfasserin |4 aut | |
| 700 | 1 | |a Pochtovyi, Andrey A |e verfasserin |4 aut | |
| 700 | 1 | |a Komissarov, Andrey B |e verfasserin |4 aut | |
| 700 | 1 | |a Kleymenov, Denis A. |e verfasserin |4 aut | |
| 700 | 1 | |a Kuznetsova, Nadezhda A |e verfasserin |4 aut | |
| 700 | 1 | |a Tukhvatulin, Amir I |e verfasserin |4 aut | |
| 700 | 1 | |a Zubkova, Olga V |e verfasserin |4 aut | |
| 700 | 1 | |a Dzharullaeva, Alina S |e verfasserin |4 aut | |
| 700 | 1 | |a Kovyrshina, Anna V |e verfasserin |4 aut | |
| 700 | 1 | |a Lubenets, Nadezhda L |e verfasserin |4 aut | |
| 700 | 1 | |a Grousova, Daria M |e verfasserin |4 aut | |
| 700 | 1 | |a Erokhova, Alina S |e verfasserin |4 aut | |
| 700 | 1 | |a Izhaeva, Fatima M |e verfasserin |4 aut | |
| 700 | 1 | |a Popova, Olga |e verfasserin |4 aut | |
| 700 | 1 | |a Ozharovskaya, Tatiana A |e verfasserin |4 aut | |
| 700 | 1 | |a Semikhin, Alexander S |e verfasserin |4 aut | |
| 700 | 1 | |a Tokarskaya, Elizaveta A |e verfasserin |4 aut | |
| 700 | 1 | |a Shmarov, Maksim M |e verfasserin |4 aut | |
| 700 | 1 | |a Nikitenko, Natalia A |e verfasserin |4 aut | |
| 700 | 1 | |a Shidlovskaya, Elena V |e verfasserin |4 aut | |
| 700 | 1 | |a Bykonia, Evgeniia N. |e verfasserin |4 aut | |
| 700 | 1 | |a Mazunina, Elena P. |e verfasserin |4 aut | |
| 700 | 1 | |a Divisenko, Elizaveta V |e verfasserin |4 aut | |
| 700 | 1 | |a Vasilchenko, Lyudmila A |e verfasserin |4 aut | |
| 700 | 1 | |a Popova, Liubov I. |e verfasserin |4 aut | |
| 700 | 1 | |a Danilenko, Daria M |e verfasserin |4 aut | |
| 700 | 1 | |a Lioznov, Dmitry A |e verfasserin |4 aut | |
| 700 | 1 | |a Tkachuk, Artem P |e verfasserin |4 aut | |
| 700 | 1 | |a Borisevich, Sergei V |e verfasserin |4 aut | |
| 700 | 1 | |a Naroditsky, Boris S |e verfasserin |4 aut | |
| 700 | 1 | |a Logunov, Denis Y |e verfasserin |4 aut | |
| 700 | 1 | |a Gintsburg, Alexander L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2021) vom: 16. Okt. |
| 773 | 1 | 8 | |g year:2021 |g day:16 |g month:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.10.08.21264715 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 16 |c 10 | ||
| 953 | |2 045F |a 570 | ||